Rival Drugmakers Now Compete For FDA Warnings

By Ed Silverman This may be a case of taking competition to a new low. Late last month, the FDA Office of Prescription Drug Program issued so-called untitled letters to a pair of drugmakers ...

AstraZeneca, PTSD And A Buried Seroquel Study

By Ed Silverman File this under ‘hidden clinical trial disorder.’ For a decade, the US military regularly prescribed its service members atypical antipsychotics, which are approved ...

How Payers View Combo Therapy For Prostate Cancer

By Ed Silverman The recent spurt of available treatments for prostate cancer may prove encouraging for patients and physicians, the price tags for these medications are giving insurers ...

The Pfizer Viagra Patent Goes Limp In Canada

By Ed Silverman Here is a ruling that is making the Pfizer executive team stand up and take notice. The Supreme Court of Canada decided unanimously that the patent on the Viagra erectile ...

Will Merck’s Oxytrol benefit from new FDA interest in OTC access?

By Tracy Staton Merck wants to sell the bladder drug Oxytrol over the counter. Naturally, it has asked FDA for permission to do so. And now, the agency is preparing for an advisory ...

Long-term study reinforces safety record of blockbuster Pradaxa

By Eric Palmer Just days after the FDA said it had found that rates of gastrointestinal or intracranial bleeding were no more prevalent for patients taking the blood thinner Pradaxa than ...

Sun joins dermatology rush with $230M DUSA buyout

By Tracy Staton Dermatology is hot. Valeant Pharmaceuticals ($VRX) has been snapping up skin-remedy companies, including its recent $2.6 billion deal for Medicis. Novartis’ generics ...

Cipla slashes prices on another cancer-drug trio

Indian company targets Roche’s Tarceva with new 63% discount By Tracy Staton Cipla is roiling the waters in India again. Six months after slashing the prices on three cancer ...

GSK, XenoPort part ways after Horizant disappointment

By Tracy Staton GlaxoSmithKline ($GSK) is punting on Horizant. The U.K.-based drugmaker is kicking the restless legs syndrome drug back to partner XenoPort after a series of setbacks, ...

GenMark’s revenue soars as loss narrows

By Damian Garde GenMark Diagnostics ($GNMK) posted a fourfold revenue jump in the third quarter, as the company increased its analyzer placements and boosted its reagent sales by almost ...

Boston Scientific facing 2,500 lawsuits over vaginal mesh

By Damian Garde Boston Scientific ($BSX) is among the many devicemakers coping with the fallout over vaginal mesh implants, and the company has now disclosed that it’s facing ...

Theragenics revenue disappoints

The surgical products maker says the economy, healthcare reform and the device tax create major challenges By Mark Hollmer Theragenics ($TGX) blames the “headwinds” of ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS